LCMS,
FTIR,
Single Crystal X-Ray Diffractometer
*FTIR, Fourier transform infrared spectroscopy; GCMS, gas chromatography mass spectrometer; HPLC, high-performance liquid chromatography; LCMS, liquid chromatography mass spectrometer; NMR, nuclear magnetic resonance; qRTPCR, qualitative real-time polymerase chain reaction; UV-VIS, ultraviolet visible spectrometer.
Finding funding to purchase equipment can be problematic. While this is far from unique to Ghana, it is particularly problematic here, as individual universities cannot afford many pieces of equipment and it is very difficult to find external funding opportunities for large equipment grants. None of the major equipment suppliers have bases in West Africa, generally resulting in equipment being brought in, typically from Europe or the USA. When trying to decide on the procurement of large pieces of equipment, it becomes very challenging to demo equipment and ascertain its suitability. Once an item is purchased, installation engineers need to be flown in from abroad, which adds significantly to both cost and time. General servicing and maintenance can also involve flying in specialist engineers again adding to costs and often resulting in large periods where the instruments are not functioning. This whole process can be further hampered by the lack of availability of spare parts. Therefore, when purchasing any new equipment, funding should be identified to maintain them.
Going forward, it will be important to train engineers within Ghana to be able to service and maintain pieces of equipment. It would also be prudent to find a mechanism to supply the more commonly used spare parts within Ghana or at least within West Africa. Local support staff need to be trained in more sophisticated maintenance of the equipment. There also needs to be enhanced staff training in both the use of the equipment and interpretation of the data. Making this cross-institutional would facilitate a critical mass and allow institutions to aid one another. By way of example, at KNUST, a shared laboratory of equipment has been pooled together in the “KNUST Central Laboratory”. This facility allows researchers access to state-of-the-art technologies that would have been too expensive for individual departments to procure and maintain.
There are some promising signs in terms of infrastructure. The NMIMR has recently moved into a new state-of-the-art facility. The Central Laboratory at KNUST has very good modern laboratories, and there is a new University, the University of Health and Allied Sciences (UHAS), which has just built a new facility. The Science Annex building at UCC is near completion and is expected to provide modern laboratory space and facilities.
However, there is still a need for extra infrastructural development across all the Institutions in Ghana. For instance, there is a need for new chemistry laboratories for synthetic chemistry because the existing buildings are old and were not designed for synthetic chemistry research. In addition, the majority of the laboratory space in the existing building is dedicated to undergraduate teaching. The current chemistry research laboratories have limited space available for research activities. In the medium term, it would be possible to fit additional fume chambers into the existing laboratories to enable synthetic small molecule drug discovery research. However, in the long term, a new building with appropriate facilities for synthetic chemistry is required.
This is one of the major challenges facing scientists in Ghana. Quicker access to research items would ensure meeting project timelines and delivery of proposed project goals. However, the process of procurement in Ghana is complex, with many bureaucratic layers. Science research is data-driven and timebound; therefore, delays in getting consumables and supplies are a huge disadvantage for researchers in Ghana. It impacts heavily on making projections and planning future research activities.
Most research items cannot be purchased directly from within Ghana, and they must be imported. The local companies who sell most of these items are third-party agents who themselves must import into the country before selling to prospective end users. Importation is further plagued with additional layers of challenges including complex shipping arrangements. Sometimes shipping can be by air, but other times is required by sea, extending further the time for delivery. These delays and challenges can be problematic with temperature-sensitive goods where a cold chain is required. All these factors can sometimes lead to the actual cost of an item being significantly more expensive than the advertised price by the supplier or the manufacturer.
Another important challenge is the payment process. Often the institutions, and for that matter, the procurement law, demands that payments are made for goods that have been supplied, inspected, and certified by the requisite authorities [ 15 ]. However, the suppliers, particularly the foreign suppliers, demand payment in advance. These bottlenecks compel the researcher to go through a third party (those who subscribe to prefinancing) with the consequence of paying more for the same items. In limited instances where credit is granted, if the payment to the supplier takes longer than stated in the agreements, it can reduce the chance of the researcher benefiting from any future credit from that supplier.
There is willingness to collaborate across institutions, but there is a need to develop structures to enable this. Drug discovery research would involve management of facilities across institutions. For example, management of equipment scheduling; tracking of chemicals, reagents, and samples; and cost recovery for equipment use. To support this, we have compiled a list of all existing core equipment across institutions and their locations. Efforts are underway to develop scheduling management systems to allow researchers at different institutions to book time on core equipment at other institutions. We hope to use IT resources to proficiently handle booking on required equipment ahead of time. Chemical inventories could be integrated to allow researchers across institutions to easily see what is available and can be borrowed from other laboratories, but this would require discussions with management across institutions.
Our long-term vision is to develop drug discovery research capabilities in Ghana, to a level where we can produce preclinical candidates and move towards partnership for clinical studies.
A key requirement to realise this vision is for the research-active Universities and research centres to work together to address the challenges highlighted above. While this initiative has been hindered by the Coronavirus Disease 2019 (COVID-19) pandemic, we have now formed working groups to bring together key staff within the different institutions. These are synthetic chemistry, analytical chemistry, pathogen screening, and natural product chemistry. Further working groups are being considered, including DMPK and computational chemistry. In addition, we have put in place a cross-institutional working group, to look at more strategic issues. These working groups have several aims:
By way of examples
Our vision is that by working together, we can start to overcome some of the challenges to develop further drug discovery research capabilities within Ghana and more widely within the West African region. Other challenges require infrastructural changes that are beyond our control. However, by coming together, we hope to speak in one voice and highlight these issues to all stakeholders for the desired change.
We are aiming to develop research programmes and to build our drug discovery research expertise and infrastructure around these programmes. Initially, this will be facilitated by interaction with external partners, such as the WCAIR and H3D Centre at the University of Cape Town (UCT) in South Africa, and support of funding agencies such as Medicines for Malaria Venture (MMV). However, as we develop our infrastructure and capabilities, we aim to internalise more of this research within Ghana. An excellent example of this approach is the way that H3D has developed at the UCT in South Africa. They initiated projects with MMV in malaria and developed a preclinical candidate. This was done in collaboration with others, such as the Swiss Tropical and Public Health Institute (SwissTPH). However, they have leveraged their success to eventually develop sophisticated malaria testing capabilities, DMPK, and clinical development experience. Another important aspect is to develop further our South–South interactions, particularly with researchers in the West African region.
We also think that it is important to focus on areas of unmet medical need that are relevant to Ghana and offer solutions that are appropriate to the context within Ghana. There are many infectious diseases that are poorly treated clinically and are of public health importance in Ghana. For example, Ghana is one of the countries with the highest levels of TB endemic countries in the world with an estimated national TB prevalence of 290 cases per 100,000 population and also a low case detection rate, estimated to be 20.7% [ 20 ]. This means that approximately 80% of TB cases go undiagnosed with its concomitant public health implications. Also, Ghana is among the 15 highest countries for malaria endemicity, with 2% of the global malarial cases and 3% deaths [ 21 ].
We have obtained funding from the Academy of Medical Sciences to allow networking within Ghana and to bring together senior representatives of our universities to support our vision. Unfortunately, like many things, this has been affected by the COVID-19 crisis. However, our initial meeting has led to the formation of online focus groups, and we hope to bring together people in person soon.
While developing drug discovery research in Ghana will undoubtably be a long road, we are encouraged by the steps we have taken so far. As we progress, further challenges will be identified but working together as a group of institutions, we hope that we can overcome these to fulfil our vision.
Funding was received from the Academy of Medical Sciences (D. Y.-M.; I. H.G., GCRFNGR5\1213) and Wellcome for funding the Wellcome Centre for Anti-Infectives Research (203134/Z/16/Z). The funding was to support bringing together funders and scientist involved in Drug Discovery research in Ghana in a networking workshop. The funders had no role in the decision to publish manuscript and in the preparation.
Free stories left to read
Skift Pro subscribers get unlimited access to essential travel industry news
Dawit Habtemariam , Skift
June 24th, 2024 at 4:00 PM EDT
Portland is going to need another tourism champion, one who will be an outspoken advocate.
Dawit Habtemariam
Portland is losing a tourism champion. Jeff Miller , who has served for 19 years as CEO and president of Travel Portland , the city’s destination marketing organization, will retire in December, reported Northstar Meetings Group .
Miller oversaw the city’s tourism recovery and led a staff of about 70 full- and part-time employees and an annual budget of about $30 million. He defended Portland’s image against negative media associations with crime and violence. News outlets had repeatedly shown images of the city in a doom loop years after the civil unrest surrounding the murder of George Floyd subsided.
“What the press has reported on Portland has changed dramatically,” Miller told Skift last June . “Now, if we can just get them to stop using pictures from three years ago, we will be fine.”
Portland had to fill the gap left by conventions pulling out amid the unrest. “During the pandemic, with a hundred days of protest and all of the violence and all the reporting, most cities rebooked [conventions] into future years. And we did too, but not to the degree that other cities did,” Miller told Skift in September.
“Our team has done an amazing job of filling those holes, but there are more to be filled,” he said.
A major objective of Miller was to reignite suburbanite interest in visiting Portland’s downtown.
The share of Portlanders who would recommend the city to out-of-town friends and family fell from 88 percent in 2017 to 61 percent in 2023 , with most of the negative sentiment concentrating in the suburbs, according to Travel Portland.
Miller pointed to the spread of remote work and negative media coverage as the reasons why suburbanite sentiment dropped.
“The reputational damage that Portland suffered certainly extended locally and Portlanders have always been very, very proud of their city,” said Miller. “I think it’s taken a bit of time to get people back into the core to see what’s going on.”
Miller publicly spoke out in support of a ban on public drug use. In November 2020, Oregon approved ballot Measure 110, decriminalizing possession of small amounts of controlled substances.
Miller spoke up on the impact of public drug use on the city’s tourism industry. “Portland’s hospitality crisis is in crisis, and it can be linked to the conditions on our streets with open drug dealing and usage,” he told the city council at a hearing in September .
In that same month, Portland’s city council passed an ordinance that banned the use of controlled substances on public property.
“We need to make major and significant changes, compassionate changes, but we need to find places for these people to get off the street,” Miller told Skift in September.
Miller spoke on-stage at the Skift Global Forum in New York last September.
Our daily coverage of the global travel industry. Written by editors and analysts from across Skift’s brands.
Have a confidential tip for Skift? Get in touch
Tags: ceos , destination marketing organizations , dmos , executives , portland , tourism
1 of 2 free stories left to read
An official website of the United States government
Here’s how you know
Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Find more resources on lgbtqi+ health.
Advertisement
Supported by
An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
By Andrew Jacobs
An independent advisory panel of the Food and Drug Administration rejected the use of MDMA-assisted therapy for post-traumatic stress disorder on Tuesday, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as Ecstasy.
Before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, Lykos Therapeutics. Many questions focused on the fact that study participants were by and large able to correctly guess whether they had been given MDMA, also known by the names of Ecstasy or molly.
The panel voted 9-2 on whether the MDMA-assisted therapy was effective, and voted 10-1 on whether the proposed treatment’s benefits outweighed its risks.
Other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. A case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds.
Many of the committee members said they were especially worried about the failure of Lykos to collect detailed data from participants on the potential for abuse of a drug that generates feelings of bliss and well-being.
“I absolutely agree that we need new and better treatments for PTSD,” said Paul Holtzheimer, deputy director for research at the National Center for PTSD, a panelist who voted no on the question of whether the benefits of MDMA-therapy outweighed the risks.
We are having trouble retrieving the article content.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.
Thank you for your patience while we verify access.
Already a subscriber? Log in .
Want all of The Times? Subscribe .
Loading metrics
Open Access
Viewpoints are opinion pieces grounded in evidence on topics of broad interest to the journal's readership.
See all article types »
* E-mail: [email protected]
Affiliation Department of Chemistry, University of Ghana, Legon-Accra, Ghana
Affiliation Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, Legon-Accra, Ghana
Affiliation Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon- Accra, Ghana
Affiliation Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana
Affiliation Department of Chemistry, School of Physical Sciences, University of Cape Coast, Cape Coast, Ghana
Affiliation Department of Microbiology, Centre for Plant Medicine, Mampong-Akuapem, Ghana
Affiliation Department of Pharmaceutical Chemistry, School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana
Affiliation Department of Pharmacognosy, Faculty of Pharmacy and Pharmaceutical Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana
Affiliation Holistic Drug Discovery and Development (H3D) Centre at the University of Cape Town (UCT), Rondebosch, South Africa
Affiliation Wellcome Centre for Anti-Infectives Research (WCAIR), Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, United Kingdom
Affiliation Department of Clinical Pathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana
Published: September 15, 2022
We have a long-term vision to develop drug discovery research capacity within Ghana, to tackle unmet medical needs in Ghana and the wider West African region. However, there are several issues and challenges that need to be overcome to enable this vision, including training, human resource, equipment, infrastructure, procurement, and logistics. We discuss these challenges from the context of Ghana in this review. An important development is the universities and research centres within Ghana working together to address some of these challenges. Therefore, while there is a long way to go to fully accomplish our vision, there are encouraging signs.
Citation: Amewu RK, Amoateng P, Arthur PK, Asare P, Asiamah I, Boamah D, et al. (2022) Drug discovery research in Ghana, challenges, current efforts, and the way forward. PLoS Negl Trop Dis 16(9): e0010645. https://doi.org/10.1371/journal.pntd.0010645
Editor: Felix Bongomin, Gulu University, UGANDA
Copyright: © 2022 Amewu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was received from the Academy of Medical Sciences (D. Y.-M.; I. H.G., GCRFNGR5\1213) and Wellcome for funding the Wellcome Centre for Anti-Infectives Research (203134/Z/16/Z). The funding was to support bringing together funders and scientist involved in Drug Discovery research in Ghana in a networking workshop. The funders had no role in the decision to publish manuscript and in the preparation.
Competing interests: The authors have declared that no competing interests exist.
There is limited drug discovery research in sub-Saharan Africa [ 1 ], with the notable exception of Holistic Drug Discovery and Development (H3D), which is based in Cape Town. Hence, we recognized the value in outlining our vision and the progress made in Ghana towards the development of drug discovery research and to highlight some of the challenges that we face. There is a huge need for new drugs for Ghana and across sub-Saharan Africa, particularly in the anti-infective area. Diseases such as malaria, leishmaniasis, schistosomiasis, and tuberculosis (TB) have a massive impact in Ghana, and yet there is inadequate research in drug discovery into these diseases locally. Due to the economics of drug discovery research, there is little commercial gain to be made from drugs for such diseases. Furthermore, for noncommunicable diseases such as cancer, the approaches of diagnosis and management are often very different in countries such as Ghana, from high-income countries, necessitating research in these areas too.
Various efforts are underway in Ghana to increase drug discovery research efforts. In this article, we discuss the status quo and some of the challenges facing drug discovery research in Ghana. Furthermore, we discuss the opportunities going forward with emphasis on the preclinical development stages. Our overall vision is to grow the current infrastructure to enable integrated and professional drug discovery activities: screening of compounds, compound optimisation, and compound characterisation. The eventual aim is to be able to produce preclinical drug candidates.
Developing a drug discovery research infrastructure will address some of the United Nations Strategic Development Goals (SDGs), highlighted in Fig 1 [ 2 ], giving many additional benefits to Ghana. These benefits include education and training across many disciplines to create an environment for Ghanaian researchers to flourish. Furthermore.it offers the potential for generation of “spin-out” companies research groups to generate innovation and economic development. Moreover, building up drug discovery research gives opportunities to strengthen South–South interactions within the West Africa subregion through collaborative research ultimately, we hope this work will lead to the discovery of candidate medicines.
https://doi.org/10.1371/journal.pntd.0010645.g001
In Ghana, there are a number of key universities and research institutions that have an ambition for drug discovery research ( Fig 2 ). These include the University of Ghana (UG), Accra; Kwame Nkrumah University of Science and Technology (KNUST), Kumasi; University of Cape Coast (UCC), Cape Coast; and the University of Health and Allied Sciences (UHAS), Ho. A constituent part of UG is the Noguchi Memorial Institute of Medical Research (NMIMR), with excellent infrastructure, including Biosafety Level 3 (BSL3) laboratories, an animal experimentation facility for pathogen studies and clinical trials unit. In addition, the Centre for Plant Medicine Research (CPMR), Mampong carries out research on herbal medicines.
*This was determined based on publications in drug discovery and through records of collaborations across the institutions. The base map used for constructing the map as well as the copyright information for use of the base map files are freely available at https://data.humdata.org/dataset/cod-ab-gha . No changes were made to the base map files.
https://doi.org/10.1371/journal.pntd.0010645.g002
Drug discovery has multiple requirements, many of which have been initiated in Ghana. Pathogen screening has been developed at multiple sites. There is a significant amount of work, trying to take advantage of small molecules from natural sources such as plants, marine invertebrates, fungi, and bacteria. Some of this research is guided by traditional medicine, with the aim of identifying the active constituents. These chemical investigations have yielded many structurally unique compound classes including clerodane diterpenes [ 3 ], flavonoid glycosides [ 4 ], prenylated aryl benzofurans [ 5 ], indole alkaloids, [ 6 ] benzophenanthridines [ 7 ], dichapetalins [ 8 – 10 ], isoflavones [ 11 ], legonmycins [ 12 ], and accramycins [ 13 , 14 ] which have exhibited promising activities following screening in several anti-infective assays. More recently, drug discovery using small synthetic molecules is being developed. Furthermore, there are various research groups, elucidating the underlying mechanisms of diseases as well as identifying and validating targets for therapeutic interventions.
There are several key challenges that we have identified as confronting drug discovery research in Ghana. We anticipate that many of these will be similar to other sub-Saharan African countries and that any knowledge gained should be shared to support research projects in the continent more widely.
Ghana has a well-developed and thriving tertiary education system, which trains people in the basic science disciplines such as chemistry, biochemistry, and microbiology. However, there is a need for training in more specialised aspects in areas such as drug discovery. Firstly, in how to carry out drug discovery research, understanding the different stages and requirements, and how to integrate the basic disciplines. Secondly, other required disciplines are largely absent, such as drug metabolism and pharmacokinetics (DMPK). People need to be trained in these techniques, and relevant assays need to be established in Ghana. It is also important people learn how to interpret and share these data with colleagues working in other disciplines and work together to make decisions on research project progression.
The younger generation, who are quicker to adopt modern technology, need to be trained to complement the efforts of the current scientists. Expertise in the use of robotics, data processing software, and computational chemistry techniques, including machine learning and artificial intelligence, are needed.
There is also a need for training in the use and maintenance of the scientific equipment. Some of the equipment in Ghana is underutilized, obsolete, or in poor working condition owing to an absence of expertise and regular maintenance. The underutilization of working equipment and frequent breakdowns of equipment point to the need to train more technical staff. Training needs to focus on hands-on use and maintenance to ensure maximum and proper utilization of equipment. Focussing the training on technical staff is advantageous as there is usually less turnover in this category of staff, although they manage and operate the equipment. Using bidirectional staff exchange programmes between industry and educational institutions’ technical staff can build the needed capacity at little cost.
There is little funding for researchers to carry out studies in Ghana. Most staff at the Principal Investigator level have high teaching and administrative duties, leaving little time for research. Funding for postdoctoral staff from internal university sources is limited, and external funding is often limited to larger, more competitive grant applications. PhD and Master’s students often have to self-fund due to a lack of funding opportunities, leading to many students not continuing in academia as they cannot afford to.
These funding issues lead to a culture of students carrying out placements or entire degrees at institutes outside of Ghana, especially in the drug discovery field since opportunities are limited. Some get the opportunity for further study in South Africa, but many move to Europe or the USA for further degrees. Many pharmaceutical companies and institutions run training schemes for limited periods, which is an excellent way to upskill individuals. However, without sufficient infrastructure and dedicated time for research at their home institution, it can be difficult to put learnings into practice.
All these factors culminate in limited number of individuals working in Ghana on drug discovery. The networking between universities is therefore essential to allow a critical mass of researchers across the country to work together to further drug discovery research.
Most of the critical equipment is in place, albeit not all are located at the same University ( Table 1 ). However, there are still equipment needs, for example, LC-MS-MS equipment and robotic equipment for high-throughput compound screening. Some equipment needs to be duplicated between institutes, to prevent the delays and complexities of transferring samples between institutions.
https://doi.org/10.1371/journal.pntd.0010645.t001
Finding funding to purchase equipment can be problematic. While this is far from unique to Ghana, it is particularly problematic here, as individual universities cannot afford many pieces of equipment and it is very difficult to find external funding opportunities for large equipment grants. None of the major equipment suppliers have bases in West Africa, generally resulting in equipment being brought in, typically from Europe or the USA. When trying to decide on the procurement of large pieces of equipment, it becomes very challenging to demo equipment and ascertain its suitability. Once an item is purchased, installation engineers need to be flown in from abroad, which adds significantly to both cost and time. General servicing and maintenance can also involve flying in specialist engineers again adding to costs and often resulting in large periods where the instruments are not functioning. This whole process can be further hampered by the lack of availability of spare parts. Therefore, when purchasing any new equipment, funding should be identified to maintain them.
Going forward, it will be important to train engineers within Ghana to be able to service and maintain pieces of equipment. It would also be prudent to find a mechanism to supply the more commonly used spare parts within Ghana or at least within West Africa. Local support staff need to be trained in more sophisticated maintenance of the equipment. There also needs to be enhanced staff training in both the use of the equipment and interpretation of the data. Making this cross-institutional would facilitate a critical mass and allow institutions to aid one another. By way of example, at KNUST, a shared laboratory of equipment has been pooled together in the “KNUST Central Laboratory”. This facility allows researchers access to state-of-the-art technologies that would have been too expensive for individual departments to procure and maintain.
There are some promising signs in terms of infrastructure. The NMIMR has recently moved into a new state-of-the-art facility. The Central Laboratory at KNUST has very good modern laboratories, and there is a new University, the University of Health and Allied Sciences (UHAS), which has just built a new facility. The Science Annex building at UCC is near completion and is expected to provide modern laboratory space and facilities.
However, there is still a need for extra infrastructural development across all the Institutions in Ghana. For instance, there is a need for new chemistry laboratories for synthetic chemistry because the existing buildings are old and were not designed for synthetic chemistry research. In addition, the majority of the laboratory space in the existing building is dedicated to undergraduate teaching. The current chemistry research laboratories have limited space available for research activities. In the medium term, it would be possible to fit additional fume chambers into the existing laboratories to enable synthetic small molecule drug discovery research. However, in the long term, a new building with appropriate facilities for synthetic chemistry is required.
This is one of the major challenges facing scientists in Ghana. Quicker access to research items would ensure meeting project timelines and delivery of proposed project goals. However, the process of procurement in Ghana is complex, with many bureaucratic layers. Science research is data-driven and timebound; therefore, delays in getting consumables and supplies are a huge disadvantage for researchers in Ghana. It impacts heavily on making projections and planning future research activities.
Most research items cannot be purchased directly from within Ghana, and they must be imported. The local companies who sell most of these items are third-party agents who themselves must import into the country before selling to prospective end users. Importation is further plagued with additional layers of challenges including complex shipping arrangements. Sometimes shipping can be by air, but other times is required by sea, extending further the time for delivery. These delays and challenges can be problematic with temperature-sensitive goods where a cold chain is required. All these factors can sometimes lead to the actual cost of an item being significantly more expensive than the advertised price by the supplier or the manufacturer.
Another important challenge is the payment process. Often the institutions, and for that matter, the procurement law, demands that payments are made for goods that have been supplied, inspected, and certified by the requisite authorities [ 15 ]. However, the suppliers, particularly the foreign suppliers, demand payment in advance. These bottlenecks compel the researcher to go through a third party (those who subscribe to prefinancing) with the consequence of paying more for the same items. In limited instances where credit is granted, if the payment to the supplier takes longer than stated in the agreements, it can reduce the chance of the researcher benefiting from any future credit from that supplier.
There is willingness to collaborate across institutions, but there is a need to develop structures to enable this. Drug discovery research would involve management of facilities across institutions. For example, management of equipment scheduling; tracking of chemicals, reagents, and samples; and cost recovery for equipment use. To support this, we have compiled a list of all existing core equipment across institutions and their locations. Efforts are underway to develop scheduling management systems to allow researchers at different institutions to book time on core equipment at other institutions. We hope to use IT resources to proficiently handle booking on required equipment ahead of time. Chemical inventories could be integrated to allow researchers across institutions to easily see what is available and can be borrowed from other laboratories, but this would require discussions with management across institutions.
Our long-term vision is to develop drug discovery research capabilities in Ghana, to a level where we can produce preclinical candidates and move towards partnership for clinical studies.
A key requirement to realise this vision is for the research-active Universities and research centres to work together to address the challenges highlighted above. While this initiative has been hindered by the Coronavirus Disease 2019 (COVID-19) pandemic, we have now formed working groups to bring together key staff within the different institutions. These are synthetic chemistry, analytical chemistry, pathogen screening, and natural product chemistry. Further working groups are being considered, including DMPK and computational chemistry. In addition, we have put in place a cross-institutional working group, to look at more strategic issues. These working groups have several aims:
By way of examples
Our vision is that by working together, we can start to overcome some of the challenges to develop further drug discovery research capabilities within Ghana and more widely within the West African region. Other challenges require infrastructural changes that are beyond our control. However, by coming together, we hope to speak in one voice and highlight these issues to all stakeholders for the desired change.
We are aiming to develop research programmes and to build our drug discovery research expertise and infrastructure around these programmes. Initially, this will be facilitated by interaction with external partners, such as the WCAIR and H3D Centre at the University of Cape Town (UCT) in South Africa, and support of funding agencies such as Medicines for Malaria Venture (MMV). However, as we develop our infrastructure and capabilities, we aim to internalise more of this research within Ghana. An excellent example of this approach is the way that H3D has developed at the UCT in South Africa. They initiated projects with MMV in malaria and developed a preclinical candidate. This was done in collaboration with others, such as the Swiss Tropical and Public Health Institute (SwissTPH). However, they have leveraged their success to eventually develop sophisticated malaria testing capabilities, DMPK, and clinical development experience. Another important aspect is to develop further our South–South interactions, particularly with researchers in the West African region.
We also think that it is important to focus on areas of unmet medical need that are relevant to Ghana and offer solutions that are appropriate to the context within Ghana. There are many infectious diseases that are poorly treated clinically and are of public health importance in Ghana. For example, Ghana is one of the countries with the highest levels of TB endemic countries in the world with an estimated national TB prevalence of 290 cases per 100,000 population and also a low case detection rate, estimated to be 20.7% [ 20 ]. This means that approximately 80% of TB cases go undiagnosed with its concomitant public health implications. Also, Ghana is among the 15 highest countries for malaria endemicity, with 2% of the global malarial cases and 3% deaths [ 21 ].
We have obtained funding from the Academy of Medical Sciences to allow networking within Ghana and to bring together senior representatives of our universities to support our vision. Unfortunately, like many things, this has been affected by the COVID-19 crisis. However, our initial meeting has led to the formation of online focus groups, and we hope to bring together people in person soon.
While developing drug discovery research in Ghana will undoubtably be a long road, we are encouraged by the steps we have taken so far. As we progress, further challenges will be identified but working together as a group of institutions, we hope that we can overcome these to fulfil our vision.
IMAGES
VIDEO
COMMENTS
Step 1: select and recruit a target audience of policymakers or community leaders: the study was conducted with the help of community leaders and the Korle-Bu Teaching Hospital´s drug addiction unit. Step 2: recruit a group of photovoice participants: a purposeful sampling technique was used for this exploratory study.
Furthermore, the Narcotic Drugs (Control, enforcement and Sanctions) Act, 1990 (P.N.D.C.L. 236) forbids the utilisation of narcotic drugs by any individual without legal authorization, including children. While a body of research exists on substance use in Ghana, it is essential to acknowledge some limitations associated with these studies.
Chapter 3. Drugs and Drug Control in Ghana. Joseph Appiahene-Gyam . Introduction. Ghana, a W est African country of over 24 million people (comprising of over. 98% Ghanaians and 2% foreigners); ve ...
1. Introduction. The streets throughout the world are home to millions of children [], and the circumstances on the street render these children and youth vulnerable to various kinds of psychological problems and health risks such as a high rate of sex trade [2,3,4] and substance abuse and misuse [5,6,7,8].These health risk behaviors eventually put them at elevated risk for physical and mental ...
Ghana's population was estimated at 30.8 million as of 2021 by the Ghana Statistical Service (GSS) , with 6.8 million (22.1%) of the population being children under the age of 17. Ghana now has 16 administrative regions, an increase of 6 regions from 2018, the year the study's data were gathered.
Substance Abuse among Senior High School Students in Ghana 347 counter or prescription medicines (lifetime use in the last 12 months and use in last 30 days) are currently unavailable. The most extensive research in Ghana on substance use among the youth was done by the Ministry of
For example, in an article on drug confiscation in the Ashanti region, an official of the Food and Drugs Authority asserted that "some of the reasons for the abuse of the drug included supposed enhancement of sexual drive and prolonged ejaculation" (Ghana News Agency 12.4.2018) .
Six Ghanaian newspapers with the widest readership and distributions were selected for analysis to examine health communication themes and strategies related to alcohol and/or substance misuse and other drug-related behaviors in Ghana. Newspapers were manually searched using relevant keywords. We used thematic analysis to examine 90 articles that were identified. Content themes included (1 ...
Despite the high prevalence of homelessness and substance use in Ghana, research on problematic substance use in the homeless population is scant. ... (AUDIT) and the Drug Abuse Screening Test (DAST) respectively reported substantially lower prevalence for alcohol (16%) but a similar prevalence for drugs (29%).
research report a national survey on prevalence and social consequences of substance (drug) use among second cycle and out of school youth in ghana
Yet, there is a paucity of research on alcohol or drug abuse and related disorders in Ghana due to limited research, lack of opportunities for publication, and poor record-keeping in remote areas [19]. Admittedly there has been considerable research in the last three decades on alcohol or drug abuse in some African countries though in small ...
The National Drug Control Master Plan will serve as a strategic document, providing a coherent framework for more comprehensive national drug prevention and control measures. The Plan will provide the necessary evidence-based guidance to address drug abuse, illicit drug trafficking and related crimes in Ghana.
In line with the preceding evidence, older adults in Ghana may also tend to use drugs, alcohol and tobacco and, in some instances, abuse its use, which has consequences for their health. However, the prevalence and correlates of substance use among the older population during the COVID-19 pandemic remain unknown in Ghana.
Background: The scourge of drug usage among young people in Ghana has emerged as a significant impediment to the country's sustainable growth. Substance misuse poses a severe challenge, particularly in underdeveloped nations like Ghana, acting as a catalyst for economic woes and exerting a profound impact on the socioeconomic, public health, social, and individual facets of the nation.
Substance abuse research report. 01 August 2003. A national survey on the prevalence and social consequences of the substance use among second cycle and out of school youth. Drug abuse has become a global phenomenon affecting almost every country though the extent and characteristics vary depending on the country in question. The most commonly ...
This article represents a preliminary effort to describe drug abuse in Tudu, one of a number of neighborhoods in Accra that serve as drug centers. The problems of such neighborhoods reflect the drug problems that currently beset the rest of Ghana and Accra in particular. There is almost no fundamental current research on this issue.
Marijuana has been identified as the major drug of abuse among the youth in Ghana. The age of incidence of abuse of marijuana is relatively low, 10 -12 years and experimentation has been found to ...
people in Ghana, as a result of insufficient data on the dynamics of tramadol abuse in the country. However, the researchers as citizens and residents of Northern Ghana have observed with worry, the alarming rate at which young people of the country abuse the drug, as evidenced by various media reports. Again, anecdotal evidence
Marijuana has been identified as the major drug of abuse among the youth in Ghana. The age of incidence of abuse of marijuana is relatively low, 10 -12 years and experimentation has been found to be the main reason for the start of the abuse. African Journal of Educational Studies in Mathematics and Sciences Vol. 1, 2001: 115-120
In most situations, the illegal use of drugs leads to mental illness. A drug addict easily breaks down psychologically. The abuse of drugs such as marijuana, alcohol and tramadol provokes acts of ...
Semaglutide drugs such as Ozempic and Wegovy have become commonplace in weight loss treatment, but new research shows the drugs may also be useful in treating substance abuse. Researchers at Case Western Reserve University's School of Medicine found that semaglutide, or GLP-1 agonists, are linked to reduced incidence and recurrence of alcohol ...
INTRODUCTION: Substance abuse is an important public health issue affecting West Africa; however, there is currently a dearth of literature on the actions needed to address it. The aim of this study was to assess the risks and protective factors of substance abuse in Ghana, West Africa, using the photovoice method. METHODS: this study recruited and trained 10 participants in recovery from ...
Introduction. There is limited drug discovery research in sub-Saharan Africa [], with the notable exception of Holistic Drug Discovery and Development (H3D), which is based in Cape Town.Hence, we recognized the value in outlining our vision and the progress made in Ghana towards the development of drug discovery research and to highlight some of the challenges that we face.
Against Public Drug Abuse Miller publicly spoke out in support of a ban on public drug use. In November 2020, Oregon approved ballot Measure 110, decriminalizing possession of small amounts of ...
Selected achievements by NIDA, for a full timeline of accomplishments, see the NIH Almanac. Long Description for Timeline graphic. 1974: NIDA established as the federal focal point for research on substance use and substance use disorders.; 1975: Monitoring the Future (MTF) Survey is launched to measure trends in drug use among 12th graders and young adults.
For referrals to substance use and mental health treatment programs, call the Substance Abuse and Mental Health Administration (SAMHSA) National Helpline at 1-800-662-HELP (4357) or visit www.FindTreatment.gov to find a qualified healthcare provider in your area. For other personal medical advice, please speak to a qualified health professional.
The illegal drug is listed as a Schedule I substance, defined as having no accepted medical use and a high potential for abuse. Should it win F.D.A. approval, federal health authorities and ...
We have a long-term vision to develop drug discovery research capacity within Ghana, to tackle unmet medical needs in Ghana and the wider West African region. However, there are several issues and challenges that need to be overcome to enable this vision, including training, human resource, equipment, infrastructure, procurement, and logistics. We discuss these challenges from the context of ...